Please assess the completion status of the following clinical trial:

Trial Title: A Study Evaluating the Effect of Albiglutide on Gallbladder Emptying in Healthy Subjects

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: CROSSOVER
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE4
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Between 18 and 65 years of age~* Healthy~* Have venous access sufficient to allow for intravenous (IV) infusion and blood sampling as per protocol~* Subject's body mass index (BMI) is \>=18 kilogram (kg)/meter(m)\^2 and \<=30 kg/m\^2~* Male or~* Female: if she is not pregnant (as confirmed by a test at screening and at other timepoints), not lactating, and at least one of the following conditions applies: a) cannot bear children OR b) agrees to follow contraception requirements defined in the protocol~* Capable of giving signed informed consent~Exclusion Criteria:~* Alanine aminotransferase (ALT) \>1.5x Upper limit of normal (ULN)~* Bilirubin \>1.5xULN (isolated bilirubin \>1.5xULN is acceptable if bilirubin is fractionated and direct bilirubin \<35%)~* Current or chronic history of liver disease, or known hepatic or biliary abnormalities~* QT interval corrected for heart rate according to Fridericia's formula (QTcF) \> 450 milliseconds (msec)~* Systolic blood pressure is \>=140 millimetre (mm) mercury (Hg) at Screening~* Diastolic blood pressure is \>=90 mm Hg at Screening~* Heart rate is \>100 beats/min at Screening~* Fasting triglyceride level \>300 milligram/decilitre at Screening~* History of cholecystitis or other gallbladder disease~* History of gallstones, biliary motility dysfunction, or any condition rendering the subject unsuitable for ultrasonography assessments~* Prior cholecystectomy or any other gallbladder or biliary ducts procedure, prior ileal or gastric surgery, or any other medical procedure that precluded gallbladder emptying~* History of significant cardiovascular or pulmonary dysfunction prior to screening~* History of thyroid dysfunction~* History of intestinal obstruction, ileus, lap-band, gastrointestinal surgery or any other procedures that in the opinion of the investigator could influence gastric emptying (e.g., gastrectomy, gastric bypass)~* History of acute or chronic pancreatitis~* History of abdominal pain of unknown cause~* History of severe gastrointestinal disease, including gastroparesis, inflammatory bowel disease, Crohn's disease, or irritable bowel syndrome~* Personal or family history of multiple endocrine neoplasia type 2~* Personal or family history of medullary carcinoma of the thyroid~* Unable to refrain from the use of prescription or non-prescription drugs, including vitamins, herbal and dietary supplements (including St John's Wort) within 7 days~* Current or past use of medications that may have significantly affected gastrointestinal and/or gallbladder motility or pancreatic or hepatobiliary systems~* History of regular alcohol consumption within 6 months of the study~* Urinary cotinine levels indicative of smoking or history of regular use of tobacco- or nicotine-containing products within 3 months prior to screening~* Subject has a history of significant weight loss or is currently attempting weight loss~* History of sensitivity or contraindication to any of the study medications or components thereof or a history of drug or other allergy~* Subject has previously received any GLP-1 mimetic compound (e.g., exenatide, liraglutide, lixisenatide, dulaglutide)~* A biliary pathology as assessed by ultrasound~* An abnormal (i.e., outside the normal reference range) thyroid function test assessed by thyroid stimulating hormone at screening~* An abnormal amylase or lipase test at screening~* A positive pre-study Hepatitis B surface antigen or positive Hepatitis C antibody result~* A positive pre-study drug/alcohol screen~* A positive test for Human immunodeficiency virus (HIV) antibody~* A screening ultrasound which demonstrates inadequate imaging of gallbladder, main pancreatic duct, or common duct~* Where participation in the study would result in donation of blood or blood products in excess of 500 mL within 56-day period~* The subject participated in a clinical trial and received an investigational product within 30 days, 5 half-lives or twice the duration of the biological effect of the investigational product (whichever is longer)~* Exposure to more than 4 new chemical entities within 12 months prior to the first dosing day

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 65 Years
- Healthy Volunteers: t

Study Arms:
- Albiglutide / Placebo or Placebo / Albiglutide (Type: EXPERIMENTAL): In treatment period 1, subjects will receive Albiglutide 50 mg or Placebo subcutaneously (SC) after fasting overnight for at least 10 hours according to randomization schedule on Day 1. Subject will also receive CCK (Kinevac) infusion intravenously for a period of 50 minutes after fasting overnight for at least 10 hours on Day 4. After washout period of a minimum of 42 days in treatment period 2, subjects will receive same treatment according to randomization schedule in a cross-over fashion

Based on this trial design, predict the completion outcome and termination type (if applicable).